Inhibiting Negative Immune Regulators to Enhance Antigen Presentation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current approaches to stimulate helper T-cell activation and induce effective immune responses against pathogens and tumors are inadequate, particularly in enhancing antigen presentation and immune cell activation, leading to insufficient control of infections and cancer.

Innovation Solution

A composition that inhibits negative immune regulators such as SOCS1, A20, and SUMO proteins, using siRNA or other inhibitors to modulate immune cell activity, enhancing antigen presentation and cytokine signaling to boost immunopotency and immune response.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If negative immune regulators like SOCS1 and A20 are active in immune cells, then immune response is suppressed, but immunopotency and effective immune response are reduced

Engineering Contradiction:

Improveimmune response effectivenessVSAvoidnegative immune regulator activity

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent extracts and removes negative immune regulators (SOCS1, A20, SUMO proteins) from immune cells using siRNA or other inhibitors, thereby eliminating the harmful factor that suppresses immune response while preserving the beneficial immune function

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent converts the harmful suppressive activity of negative immune regulators into a benefit by selectively inhibiting them, allowing the immune system to achieve effective response against pathogens and tumors that would otherwise be blocked

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

2Productivity

If helper T-cell activation is stimulated using lysosomal transmembrane protein sequences, then T-cell activation is enhanced, but effective immune responses against CD8+ T cells and B cells are not induced

Engineering Contradiction:

ImproveT-cell activationVSAvoideffective immune response

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The patent changes the molecular parameters of T-cell activation by shifting from lysosomal transmembrane protein sequences to inhibition of negative immune regulators, thereby modifying the activation mechanism to achieve both CD4+ and CD8+ T-cell and B cell responses

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS7868159B2Modulation of negative immune regulators and applications for immunotherapy

Publication Date: 2011.01.11 BAYLOR COLLEGE OF MEDICINE

AI summary

The invention includes compositions and methods for enhancing immunopotency of an immune cell by way of inhibiting a negative immune regulator in the cell. The present invention provides vaccines and therapies in which antigen presentation is enhanced through inhibition of negative immune regulators. The present invention also provides a mechanism to break self tolerance in tumor vaccination methods that rely on presentation of self tumor antigens.